Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empasiprubart versus IVIg in adults with multifocal motor neuropathy
2024-516473-72-00Phase 3Authorised
- Sponsor
- argenx
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in multifocal motor neuropathy (MMN) comparing Empasiprubart arm with IVIg arm (2 arms). Primary endpoint: Change from baseline in grip strength in the most affected hand at week 24. Planned start Jul 2025; status: authorised.
02
Drugs
empasiprubartsubcuvia
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on 2024-516473-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516473-72-00.